Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia (ACCURATE)
Familial Hypercholesterolemia, Familial Hypercholesterolemia Due to Genetic Defect of Apolipoprotein B, Familial Hypercholesterolemia Due to Heterozygous LDL Receptor Mutation
About this trial
This is an interventional diagnostic trial for Familial Hypercholesterolemia focused on measuring Familial hypercholesterolemia, hyperlipoproteinemia Type II, hyperlipoproteinemia type 2, familial hypercholesterolaemia, myocardial infarction, acute coronary syndrome, ST-elevated myocardial infarction, STEMI, non-ST-elevation myocardial infarction, NSTEMI, heart attack, genetic investigation, genetic testing, proprotein convertase subtilisin kexin 9, PCSK9, low-density lipoprotein receptor, LDLR, apolipoprotein B, APOB, low-density lipoprotein cholesterol, LDL-C
Eligibility Criteria
Age <60 years
AND
Admitted to an acute cardiac unit with either:
- A ST elevation myocardial infarction (STEMI), or
- A non-ST elevation myocardial infarction (NSTEMI)
AND
Maximum lipid level at the time of admission or during the prior 1 year of
- LDL level ≥4 mmol/L (154 mg/dL) if not on a statin, or
- LDL-C level ≥2.5 mmol/L (96 mg/dL) if on a statin prior to presentation, or
- Non-HDL-C ≥4.6 mmol/L (177 mg/dL) if LDL-C not available
Sites / Locations
- Vancouver General HospitalRecruiting
- St.Pauls HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Observation
Active-testing
Those admitted in the first 6 months of the study that meet the inclusion criteria. Patients will be treated according to the normal standard of care for acute coronary syndrome.
Those admitted between 6-18 months of the study meeting the inclusion criteria. Saliva samples will be collected for DNA testing.